Shmuel Hess Sells 1,865 Shares of MediWound (NASDAQ:MDWD) Stock

MediWound Ltd. (NASDAQ:MDWD) COO Shmuel Hess sold 1,865 shares of the stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $13.00, for a total value of $24,245.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Shmuel Hess also recently made the following trade(s):

• On Thursday, August 27th, Shmuel Hess sold 3,958 shares of MediWound stock. The shares were sold at an average price of $12.92, for a total value of $51,137.36.

MediWound Stock Performance

Shares of NASDAQ MDWD traded down $0.58 during mid-day trading on Friday, reaching $12.66. The company had a trading volume of 165,534 shares, compared to its average volume of 92,786. The company has a market capitalization of $162.71 million, a price-to-earnings ratio of -7.03 and a beta of 0.15. The stock has a fifty day moving average of $14.19 and a two-hundred day moving average of $15.66. MediWound Ltd. has a 12-month low of $12.52 and a 12-month high of $20.30.

MediWound (NASDAQ:MDWD) last released its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.01). MediWound had a negative net margin of 170.10% and a negative return on equity of 47.24%. The company had revenue of $3.09 million during the quarter, compared to analyst estimates of $2.59 million. Sell-side analysts forecast that MediWound Ltd. will post -2.31 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on MDWD. HC Wainwright reiterated a “buy” rating and set a $36.00 price target on shares of MediWound in a report on Thursday, May 28th. Oppenheimer reaffirmed an “outperform” rating and set a $30.00 price objective (down from $32.00) on shares of MediWound in a research report on Friday, August 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of MediWound in a research note on Friday, July 17th. Finally, Wall Street Zen downgraded shares of MediWound from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $33.00.

Institutional Trading of MediWound

A number of institutional investors and hedge funds have recently modified their holdings of the company. Quarry LP bought a new position in MediWound in the fourth quarter worth $26,000. BNP Paribas Financial Markets increased its holdings in MediWound by 90.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 723 shares during the period. California State Teachers Retirement System raised its stake in shares of MediWound by 281.4% in the 2nd quarter. California State Teachers Retirement System now owns 2,014 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 1,486 shares in the last quarter. Russell Investments Group Ltd. raised its stake in shares of MediWound by 69.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 649 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of MediWound by 22.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after acquiring an additional 999 shares during the period. 46.83% of the stock is currently owned by institutional investors.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.